Insulin resistance, beta-cell function, adipokine profiles and cardiometabolic risk factors among Chinese youth with isolated impaired fasting glucose versus impaired glucose tolerance: the BCAMS study

Yu Li, Dan Feng, Issy C Esangbedo, Yanglu Zhao, Lanwen Han, Yingna Zhu, Junling Fu, Ge Li, Dongmei Wang, Yonghui Wang, Ming Li, Shan Gao, Steven M Willi, Yu Li, Dan Feng, Issy C Esangbedo, Yanglu Zhao, Lanwen Han, Yingna Zhu, Junling Fu, Ge Li, Dongmei Wang, Yonghui Wang, Ming Li, Shan Gao, Steven M Willi

Abstract

Objective: Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) may convey disparate risks of metabolic consequences. Fasting plasma glucose (FPG), while an expedient screening procedure, may not adequately assess metabolic risk, particularly among youths. In order to inform a strategy for screening Chinese youth for pre-diabetes, we examined the relative value of IFG versus IGT to define metabolic risk by assessing their association with insulin resistance, beta-cell dysfunction, adverse adipokine profiles and other cardiometabolic risk factors.

Research design and methods: We recruited 542 subjects (age 14-28 years) from the Beijing Child and Adolescent Metabolic Syndrome study for an in-depth assessment of cardiometabolic risk factors, including a 2-hour oral glucose tolerance test, liver ultrasound and serum levels of four adipokines.

Results: FPG failed to identify nearly all (32/33) youths with IGT, whereas 2-hour plasma glucose (2 h PG) missed 80.8% (21/26) of subjects with IFG. Impaired beta-cell function was evident from decreased oral disposition indices in those with isolated impaired fasting glucose (iIFG) or isolated impaired glucose tolerance (iIGT) versus normal glucose tolerance (NGT) (all p<0.001), whereas reduced insulin sensitivity (Matsuda) index was most pronounced in the iIGT group (p<0.01). Moreover, alterations in adipokine levels (fibroblast growth factor 21, adiponectin and leptin/adiponectin ratio) were associated with iIGT (p<0.05) but not iIFG. Youths with iIGT had a 2-fold to 32-fold increased incidence of hypertriglyceridemia, hypertension and metabolic syndrome (MetS) compared with those with NGT. In addition, subgroup analyses of participants with normal FPG revealed that the odds of having IGT increased 3-fold to 18-fold among those with elevated TGs, hypertension, moderate-to-severe non-alcoholic fatty liver disease or MetS.

Conclusions: Chinese youth with iIGT exhibit a higher cardiometabolic risk profile than those with iIFG. Thus, 2 h PG is preferred over FPG to identify the pre-diabetes phenotype at greatest risk of subsequent development of cardiovascular disease.

Trial registration number: NCT03421444.

Keywords: adipokines; impaired fasting glucose; impaired glucose tolerance; metabolic syndrome.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Figure 1Comparison of adipokine levels among the three groups. Data were presented as geometric mean (95% CI) and calculated from the general linear regression model with post hoc comparisons after controlling for age and gender. P’ values were further adjusted for BMI. Only p values of

Figure 2

Comparisons of combination efficiency to…

Figure 2

Comparisons of combination efficiency to identify the missed IGT in those with normal…

Figure 2
Comparisons of combination efficiency to identify the missed IGT in those with normal FPG. Proportions and their overlap between screening with risk of MetS (including any classical risk factor, i.e, central obesity, dyslipidaemia and high blood pressure), NAFLD, HbA1c of ≥5.7% and iIGT (FPG of
Similar articles
Cited by
References
    1. International Diabetes Federation IDF DIABETES ATLAS - 8TH EDITION. Available: http://www.diabetesatlas.org [Accessed 23 May 2018].
    1. Xu Y, Wang L, He J, et al. . Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–59. 10.1001/jama.2013.168118 - DOI - PubMed
    1. Barry E, Roberts S, Oke J, et al. . Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ 2017;356:i6538 10.1136/bmj.i6538 - DOI - PubMed
    1. American Diabetes Association Standards of medical care in diabetes-2014. Diabetes Care 2014;37:S14–80. 10.2337/dc14-S014 - DOI - PubMed
    1. Abdul-Ghani MA, Jenkinson CP, Richardson DK, et al. . Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans administration genetic epidemiology study. Diabetes 2006;55:1430–5. 10.2337/db05-1200 - DOI - PubMed
Show all 55 references
MeSH terms
Associated data
Related information
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 2
Figure 2
Comparisons of combination efficiency to identify the missed IGT in those with normal FPG. Proportions and their overlap between screening with risk of MetS (including any classical risk factor, i.e, central obesity, dyslipidaemia and high blood pressure), NAFLD, HbA1c of ≥5.7% and iIGT (FPG of

References

    1. International Diabetes Federation IDF DIABETES ATLAS - 8TH EDITION. Available: [Accessed 23 May 2018].
    1. Xu Y, Wang L, He J, et al. . Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–59. 10.1001/jama.2013.168118
    1. Barry E, Roberts S, Oke J, et al. . Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ 2017;356:i6538 10.1136/bmj.i6538
    1. American Diabetes Association Standards of medical care in diabetes-2014. Diabetes Care 2014;37:S14–80. 10.2337/dc14-S014
    1. Abdul-Ghani MA, Jenkinson CP, Richardson DK, et al. . Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans administration genetic epidemiology study. Diabetes 2006;55:1430–5. 10.2337/db05-1200
    1. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006;29:1130–9. 10.2337/dc05-2179
    1. Abdul-Ghani M, DeFronzo RA, Jayyousi A. Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter? Curr Opin Clin Nutr Metab Care 2016;19:394–9. 10.1097/MCO.0000000000000307
    1. Kanat M, Mari A, Norton L, et al. . Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes 2012;61:447–53. 10.2337/db11-0995
    1. Ferrannini E, Gastaldelli A, Miyazaki Y, et al. . Beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493–500. 10.1210/jc.2004-1133
    1. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011;108:3B–24. 10.1016/j.amjcard.2011.03.013
    1. Evans JMM, Eades CE, Leese GP. The risk of total mortality and cardiovascular mortality associated with impaired glucose regulation in Tayside, Scotland, UK: a record-linkage study in 214 094 people. BMJ Open Diabetes Res Care 2015;3:e000102 10.1136/bmjdrc-2015-000102
    1. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008;454:470–7. 10.1038/nature07202
    1. Weiss R, Santoro N, Giannini C, et al. . Prediabetes: the importance of early identification and intervention. The Lancet 2017;1:240–8.
    1. Mechanick JI, Zhao S, Garvey WT. The Adipokine-Cardiovascular-Lifestyle network: translation to clinical practice. J Am Coll Cardiol 2016;68:1785–803. 10.1016/j.jacc.2016.06.072
    1. Li S, Shin HJ, Ding EL, et al. . Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179–88. 10.1001/jama.2009.976
    1. Cameron FJ, Wherrett DK. Care of diabetes in children and adolescents: controversies, changes, and consensus. Lancet 2015;385:2096–106. 10.1016/S0140-6736(15)60971-0
    1. American Diabetes Association Classification and diagnosis of diabetes: standards of medical care in Diabetes-2019. Diabetes Care 2019;42:S13–28. 10.2337/dc19-S002
    1. Fu J, Hou C, Li L, et al. . Vitamin D modifies the associations between circulating betatrophin and cardiometabolic risk factors among Youths at risk for metabolic syndrome. Cardiovasc Diabetol 2016;15:142 10.1186/s12933-016-0461-y
    1. Feng D, Zhang J, Fu J, et al. . Association between sleep duration and cardiac structure in youths at risk for metabolic syndrome. Sci Rep 2016;6:39017 10.1038/srep39017
    1. Li M, Fisette A, Zhao X-Y, et al. . Serum resistin correlates with central obesity but weakly with insulin resistance in Chinese children and adolescents. Int J Obes 2009;33:424–39. 10.1038/ijo.2009.44
    1. Li L, Yin J, Cheng H, et al. . Identification of genetic and environmental factors predicting metabolically healthy obesity in children: data from the BCAMS study. J Clin Endocrinol Metab 2016;101:1816–25. 10.1210/jc.2015-3760
    1. Jian-gao F. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi 2010;18:163–6.
    1. Mehmood S, Margolis M, Ye C, et al. . Hepatic fat and glucose tolerance in women with recent gestational diabetes. BMJ Open Diabetes Res Care 2018;6:e000549 10.1136/bmjdrc-2018-000549
    1. Saadeh S, Younossi ZM, Remer EM, et al. . The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745–50. 10.1053/gast.2002.35354
    1. Li M, Wu C, Song A, et al. . Development and preliminary application of enzyme-linked immunosorbent assay for human net insulin in serum. Chin J Endocrinol Metab 1997;5:214–7.
    1. Li M, Yin J-hua, Zhang K, et al. . [A highly sensitive enzyme-linked immunosorbent assay for measurement of leptin secretion in human adipocytes]. Zhonghua Yi Xue Za Zhi 2008;88:3293–7.
    1. Li Q, Lu Y, Sun L, et al. . Plasma adiponectin levels in relation to prognosis in patients with angiographic coronary artery disease. Metabolism 2012;61:1803–8. 10.1016/j.metabol.2012.06.001
    1. Li G, Esangbedo IC, Xu L, et al. . Childhood retinol-binding protein 4 (RBP4) levels predicting the 10-year risk of insulin resistance and metabolic syndrome: the BCAMS study. Cardiovasc Diabetol 2018;17:69 10.1186/s12933-018-0707-y
    1. Li G, Feng D, Qu X, et al. . Role of adipokines FGF21, leptin and adiponectin in self-concept of youths with obesity. Eur Neuropsychopharmacol 2018;28:892–902. 10.1016/j.euroneuro.2018.05.015
    1. Matthews DR, Hosker JP, Rudenski AS, et al. . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9. 10.1007/BF00280883
    1. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained fro M oral glucose tolerance testing. Diabetes care 1999;22:1462–70.
    1. George L, Bacha F, Lee S, et al. . Surrogate estimates of insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to prediabetes to diabetes. J Clin Endocrinol Metab 2011;96:2136–45. 10.1210/jc.2010-2813
    1. Yeckel CW, Weiss R, Dziura J, et al. . Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004;89:1096–101. 10.1210/jc.2003-031503
    1. Gungor N, Saad R, Janosky J, et al. . Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr 2004;144:47–55. 10.1016/j.jpeds.2003.09.045
    1. Phillips DI, Clark PM, Hales CN, et al. . Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994;11:286–92. 10.1111/j.1464-5491.1994.tb00273.x
    1. Kahn SE, Prigeon RL, McCulloch DK, et al. . Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663–72. 10.2337/diab.42.11.1663
    1. American Diabetes Association Standards of medical care in diabetes--2013. Diabetes Care 2013;36:S11–66. 10.2337/dc13-S011
    1. Alberti KGMM, Eckel RH, Grundy SM, et al. . Harmonizing the metabolic syndrome: a joint interim statement of the International diabetes Federation Task force on epidemiology and prevention; National heart, lung, and blood Institute; American heart association; world heart Federation; international atherosclerosis Society; and international association for the study of obesity. Circulation 2009;120:1640–5. 10.1161/CIRCULATIONAHA.109.192644
    1. Echouffo-Tcheugui JB, Ali MK, Griffin SJ, et al. . Screening for type 2 diabetes and dysglycemia. Epidemiol Rev 2011;33:63–87. 10.1093/epirev/mxq020
    1. Aekplakorn W, Tantayotai V, Numsangkul S, et al. . Detecting prediabetes and diabetes: agreement between fasting plasma glucose and oral glucose tolerance test in Thai adults. J Diabetes Res 2015;2015:1–7. 10.1155/2015/396505
    1. Marini MA, Succurro E, Castaldo E, et al. . Cardiometabolic risk profiles and carotid atherosclerosis in individuals with prediabetes identified by fasting glucose, postchallenge glucose, and hemoglobin A1c criteria. Diabetes Care 2012;35:1144–9. 10.2337/dc11-2032
    1. Maffeis C, Pinelli L, Brambilla P, et al. . Fasting plasma glucose (Fpg) and the risk of impaired glucose tolerance in obese children and adolescents. Obesity 2010;18:1437–42. 10.1038/oby.2009.355
    1. Cali' AMG, Bonadonna RC, Trombetta M, et al. . Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. J Clin Endocrinol Metab 2008;93:1767–73. 10.1210/jc.2007-1722
    1. de Vegt F, Dekker JM, Jager A, et al. . Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA 2001;285:2109–13. 10.1001/jama.285.16.2109
    1. Huang Y, Cai X, Mai W, et al. . Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016;355:i5953 10.1136/bmj.i5953
    1. Blake DR, Meigs JB, Muller DC, et al. . Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors. DIABETES 2004;53:2005–100.
    1. Shahim B, De Bacquer D, De Backer G, et al. . The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey From the European Society of Cardiology. Diabetes Care 2017;40:1233–40. 10.2337/dc17-0245
    1. Di Bonito P, Pacifico L, Chiesa C, et al. . Impaired fasting glucose and impaired glucose tolerance in children and adolescents with overweight/obesity. J Endocrinol Invest 2017;40:409–16. 10.1007/s40618-016-0576-8
    1. Hsueh WA, Orloski L, Wyne K. Prediabetes: the importance of early identification and intervention. Postgrad Med 2010;122:129–43. 10.3810/pgm.2010.07.2180
    1. Li H, Bao Y, Xu A, et al. . Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009;94:2151–6. 10.1210/jc.2008-2331
    1. Nguyen PAH, Heggermont WA, Vanhaverbeke M, et al. . Leptin-adiponectin ratio in pre-diabetic patients undergoing percutaneous coronary intervention. Acta Cardiol 2015;70:640–6. 10.1080/AC.70.6.3120175
    1. Tönjes A, Fasshauer M, Kratzsch J, et al. . Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 2010;5:e13911 10.1371/journal.pone.0013911
    1. Morrison KM, Xu L, Tarnopolsky M, et al. . Screening for dysglycemia in overweight youth presenting for weight management. Diabetes Care 2012;35:711–6. 10.2337/dc11-1659
    1. Morandi A, Maschio M, Marigliano M, et al. . Screening for impaired glucose tolerance in obese children and adolescents: a validation and implementation study. Pediatr Obes 2014;9:17–25. 10.1111/j.2047-6310.2012.00136.x
    1. Burns SF, Bacha F, Lee SJ, et al. . Declining β-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth. Diabetes Care 2011;34:2033–40. 10.2337/dc11-0423

Source: PubMed

3
Suscribir